Article Sidebar

PDF
Date Published: 30/01/2024
Abstract Views: 301
Views PDF: 201
DOI: https://doi.org/10.51298/vmj.v534i1B.8310
Issue
Vol. 534 No. 1B (2024)
Section
Các bài báo
How to Cite
Đỗ , M. Q. ., Trần , T. K. T. ., Cao , Đình H. ., & Đào , Đức T. . (2024). SURVEY THE PREVALENCE OF METABOLIC ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES. Vietnam Medical Journal, 534(1B). https://doi.org/10.51298/vmj.v534i1B.8310

SURVEY THE PREVALENCE OF METABOLIC ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES

Minh Quân Đỗ , Thị Khánh Tường Trần , Đình Hưng Cao , Đức Tiến Đào

Main Article Content

Abstract

Objectives: Survey the prevalence of metabolic associated fatty liver disease (MAFLD) in patients with type 2 diabetes, identify relevant factors and assess the rates of hepatitis B and C virus infection and alcohol use in this patient population. Materials and methods: Cross-sectional study analyzed 163 patients with type 2 diabetes who were examined at the 175 Military Hospital from August 1st, 2022 to April 30th, 2023. Detecting fatty liver disease was made using the FibroScan compact 530 with a CAP detector. The diagnosis of MAFLD based on The Standards of European Association for the Study of the Liver (EASL) from 2020. Results: The study found that 66.3% of patients with type 2 diabetes had metabolic associated fatty liver disease with rates of mild, moderate and severe steatosis were 20.4%, 23.1% and 56.5%%, respectively. The prevalence of significant fibrosis (≥ F2), advanced fibrosis (≥ F3) and cirrhosis (F4) was 18.5%, 13.0% and 14.8%, respectively. This group also had a higher body mass index (BMI) (p<0.001) and higher triglyceride levels (p<0.05) compared to those without MAFLD. The prevalence of co-infection with hepatitis B, C virus, and alcohol abuse among MAFLD patients were 30.6%, 8.3%, and 39.8%, respectively, and no significant difference was found between the two groups. Conclusions: Metabolic associated fatty liver disease was quite common in patients with type 2 diabetes. It is important to screen for co-infection with hepatitis B and C virus and excessive alcohol consumption in this patient.

Article Details

References

1. Abu Freha N., et al. (2020), "Maternal Hepatitis B Virus or Hepatitis C Virus Carrier Status and Long-Term Endocrine Morbidity of the Offspring-A Population-Based Cohort Study", J Clin Med, 9(3).
2. Cheng K. L., et al. (2023), "Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease", J Formos Med Assoc.
3. Dharmalingam M., Yamasandhi P. G. (2018), "Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus", Indian J Endocrinol Metab, 22(3), 421-428.
4. Eslam M., et al. (2020), "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement", J Hepatol, 73(1), 202-209.
5. Guan Conghui, et al. (2022), "Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center", Journal of Diabetes Research, 2022, 8429847.
6. Huang J. F., et al. (2023), "Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease", J Clin Transl Hepatol, 11(5), 1061-1068.
7. Le N. T. D., Dinh Pham L., Quang Vo T. (2017), "Type 2 diabetes in Vietnam: a cross-sectional, prevalence-based cost-of-illness study", Diabetes Metab Syndr Obes, 10, 363-374.
8. Tuong T. T. K., et al. (2020), "Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan", Diagnostics (Basel), 10(3).
9. Ndako James A., et al. (2020), "Studies on the prevalence of Hepatitis C virus infection in diabetic patients attending a tertiary health-care facility South-west Nigeria", BMC Infectious Diseases, 20(1), 664.